Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | Director | March 30, 2012 | April 03, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date March 30, 2012 · Filed April 03, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 47,002.6379 |
Reported balance
After 2012-03-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2012-03-30 · Grant · Acquired 748.6979 · Balance 47,002.6379 F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions. |
| Common StockSEC Table I · non-derivative | Direct | 400 |
Reported balance
Holding disclosure · report date 2012-03-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 400 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 713.9831 |
Reported balance
Holding disclosure · report date 2012-03-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 713.9831 |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3: Holdings include shares acquired in dividend reinvestment transactions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2012 Filed Apr 3, 2012 15:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 748.6979 | $38.40 | $28,750.00 |
DisclosureSEC source: 0001225208-12-008835 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,002.6379 Underlying: Common Stock · 748.6979 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 30, 2011 Filed Jan 4, 2012 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 762.5995 | $37.70 | $28,750.00 |
DisclosureSEC source: 0001225208-12-000394 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,761.6355 Underlying: Common Stock · 762.5995 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 30, 2011 Filed Oct 4, 2011 17:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 879.2049 | $32.70 | $28,750.00 |
DisclosureSEC source: 0001225208-11-022664 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,474.9489 Underlying: Common Stock · 879.2049 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 30, 2011 Filed Jul 1, 2011 13:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 814.6784 | $35.29 | $28,750.00 |
DisclosureSEC source: 0001225208-11-016984 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,150.3527 Underlying: Common Stock · 814.6784 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 27, 2011 Filed May 31, 2011 14:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 4,142.5021 | $36.21 | $150,000.00 |
DisclosureSEC source: 0001225208-11-015330 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,335.6743 Underlying: Common Stock · 4,142.5021 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2011 Filed Apr 1, 2011 13:00 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 870.9482 | $33.01 | $28,750.00 |
DisclosureSEC source: 0001225208-11-010584 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,772.4522 Underlying: Common Stock · 870.9482 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2010 Filed Jan 3, 2011 17:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 658.99 | $36.04 | $23,750.00 |
DisclosureSEC source: 0001225208-11-000086 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,536.4859 Underlying: Common Stock · 658.99 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 30, 2010 Filed Oct 1, 2010 21:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 604.4553 | $36.81 | $22,250.00 |
DisclosureSEC source: 0001225208-10-021739 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,516.1109 Underlying: Common Stock · 604.4553 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 04, 2010 Filed Aug 6, 2010 14:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-10-018708 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning August 4, 2011. Read SEC document |
| June 30, 2010 Filed Jul 1, 2010 18:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 593.3657 | $34.97 | $20,750.00 |
DisclosureSEC source: 0001225208-10-015981 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,551.8066 Underlying: Common Stock · 593.3657 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 28, 2010 Filed Jun 1, 2010 20:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,632.5319 | $33.69 | $55,000.00 |
DisclosureSEC source: 0001225208-10-014304 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,958.4409 Underlying: Common Stock · 1,632.5319 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2010 Filed Apr 2, 2010 16:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 796.5194 | $37.35 | $29,750.00 |
DisclosureSEC source: 0001225208-10-009543 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,003.5753 Underlying: Common Stock · 796.5194 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2009 Filed Jan 4, 2010 19:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 814.1762 | $36.54 Strike: $0.00 | $29,750.00 |
DisclosureSEC source: 0001225208-10-000146 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,903.7659 Underlying: Common Stock · 814.1762 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 13 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2019-04-30 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $38.04 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 12 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2018-04-29 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $51.86 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 11 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2017-04-26 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $34.44 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 10 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2016-04-27 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $33.83 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 9 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2015-04-28 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $71.30 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 8 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2011-04-26 F4 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $47.23 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 7 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2014-04-29 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $65.88 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 6 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2010-04-27 F4 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $53.84 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 5 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2013-04-27 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $51.60 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 4 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2012-04-25 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 30,089.5897 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · derivative · entry 3 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,089.5897 Underlying: Common Stock · 30,089.5897 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 695.9613 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · nonDerivative · entry 2 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 695.9613 F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions"). Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021807 · doc4.xml · nonDerivative · entry 1 TATLOCK ANNE M · CIK 0001020567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.